1Pfaffl MW. A new mathematical model for relative quantification in real time RT - PCR. Nucleic Acids Res. 2001,3:11.
2Diamandis EP, Scorilas A, Fracchioli S, et al. Human kallikrein 6 (hK6) : a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Onco. 2003,6:17.
1Von Knebel Doeberitz M, Rittmuller C, Aengeneyndt P, et al.Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRB interactions. J Virol, 1994,68:2811-2821.
2Ling M, Kanayama M, Roden R, et al. Preventive and therapeutic vaccines for human papillomavirus-associated cervical cancers. J Biomed. 2000.7:341-356.
3Lin KY, Guamieri FG, Staveley-O' Carroll KF, et al, Treatment of established tumors with a novel vaccine that enhances major histocompatibility class Ⅱ presentation of tumor antigen. Cancer Res,1996,56:21-26.
4Sadovnikova E,Zhu X, Collins SM, et al. Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein. Int Immunol, 1994, 6:289-296.
5Stauss HJ, Davies H, Sadovnikova E, et al. Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in human papilloma virus. Proc Nail Acad Sci USA, 1992, 89:7871-7875.
6Meneguzzi G, Cerni C, Kieny MP, et al. Immunization against human papillomavims type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology, 1991, 181:62-69.
7Nimako M, Fiander AN, Wilkinson GW, et al. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade Ⅲ. Cancer Res, 1997, 57:4855-4861.
